Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1 + SI-B003 in extensive-stage small cell lung cancer
CTR20231886Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, SI-B003 in small cell lung cancer (SCLC), sponsored by Biokin Pharmaceutical. Started Nov 2023; status: active.
02
Drugs
izalontamab brengitecanSI-B003
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20231886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231886.